Key statistics
As of last trade, InnoCare Pharma Ltd (9969:HKG.HS) traded at 12.60, 121.44% above the 52 week low of 5.69 set on Feb 13, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 12.52 |
|---|---|
| High | 12.72 |
| Low | 12.42 |
| Bid | 12.60 |
| Offer | 12.64 |
| Previous close | 12.60 |
| Average volume | 10.48m |
|---|---|
| Shares outstanding | 1.76bn |
| Free float | 1.20bn |
| P/E (TTM) | -- |
| Market cap | 26.38bn HKD |
| EPS (TTM) | -0.1395 HKD |
Data delayed at least 15 minutes, as of Feb 13 2026 02:56 GMT.
More ▼
Announcements
- InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
- InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China
- Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
- InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
- InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
- InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
- InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
- Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
- Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
- InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
More ▼
